text.skipToContent text.skipToNavigation
Pharma & Biotech

HSMM – Human Skeletal Muscle Myoblasts

Catalog #: CC-2580

Cryopreserved ampule of Human Skeletal Muscle Myoblasts containing ≥ 500,000 cells 

Compare
EA

Product Overview

CloneticsTM Human Skeletal Muscle Myoblasts (HSMM) are isolated from normal donors. HSMMs are isolated from the upper arm or leg muscle tissue and are sold in second passage. HSMMs can be differentiated to form myotubes in culture. 

CloneticsTM HSMMs are guaranteed through 10 population doublings and to differentiate to form multinucleated myotubes in culture. All cell types test negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C are not detected for all donors and/or cell lots. A Certificate of Analysis (CoA) is provided for each cell lot purchased.

Benefits

Applications  

  • Cellular development      
  • Differentiation    
  • Diabetes    
  • Insulin uptake or resistance    
  • Tissue repair    
  • Drug development    
  • Myotube development    
  • Co-culture with other cell types

Content & Storage

Content

1 x Cryopreserved Ampule with ≥500,000 cells/vial

Instructions

Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

CytoSMARTTM 2 System

Special Sale: Up to 64% Off*

Save up to 64% when ordering a CytoSMARTTM 2 System and equip your lab now with our easy-to-use live cell monitoring device.

 

*Order by 30 November 2019 to take advantage of this special offer. Available in participating countries only.

Need a Quote or Any Support?

Are Lonza's primary cells and media applicable to your project? Do you need a quote or any help? Contact us and a local representative will get back to you.

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok